Tier 3 • HealthTech & BioTechClinical Trials
CukroScan™
Neinvazivní kontinuální monitorování glukózy pomocí optických senzorů a AI
HealthTech/Diagnostics
TAM 2035
0
Total Addressable Market
Revenue 2035
0
Projected annual revenue
Capital Required
0
Total investment needed
Team Size
0
Dedicated professionals
10-Year Revenue Projection ($M)
Market Size Evolution ($B)
Key Milestones
2025
CE Mark získán
2026
FDA approval process start
2027
Komerční launch EU
2028
FDA approval + US launch
Project Details
CategoryHealthTech/Diagnostics
Current StatusClinical Trials
Team Size22 members
Patents4 filed
Capital Requirements$18.5M
Market Position 2035
TAM
$32.6B
SAM
$14.2B
SOM
$1.9B